A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

You may be eligible if

• Patients with a histologic diagnosis confirmed from a pretreatment biopsy at the Laboratory of Pathology, NCI of one of the following entities: Diffuse small Lymphocytic Lymphoma; Follicular, Small Cleaved cell Lymphoma; Follicular, Mixed Small Cleaved and Large Cell Lymphoma; Follicular Large Cell Lymphoma; Diffuse, Intermediately Differentiated Lymphocytic Lymphoma; Diffuse, Small Cleaved Cell Lymphoma; Diffuse, Mixed Small and Large Cell Lymphoma; Diffuse, Large Cell Lymphoma; Large Cell Immunoblastic Lymphoma; Small Noncleaved Cell Lymphoma.
• Presence of CD22 antigen on at least 30 percent of tumor cells.
• Presence of objectively measurable sites of disease. Bone marrow positivity and circulating tumor cells in the peripheral blood will be considered evaluable but not measurable disease.
• No patients with purely B-cell Lymphosarcoma cell leukemia without nodal or soft tissue involvement.
• No patients with B-cell chronic lymphocytic leukemia, or B-cell or pre-B-cell acute lymphocytic leukemia, and hairy cell leukemia.
• Patients with objectively measurable disease outside a radiation port or disease which has clearly progressed within a radiation port.
• HIV negative.
• No CNS disease.
• No pulmonary parenchymal disease.
• Pleural effusions or ascites may be present.
• Patients with progression of disease despite at least one standard combination chemotherapy regimen.
• No chemotherapy for at least two weeks prior to entry.
• Patients who do not desire or are not candidates for autologous or allogeneic bone marrow transplantation procedures.
• Life expectancy of at least 3 months
• Creatinine clearance greater than 60 cc per minute.
• Total bilirubin less than 1.5 mg/dl.
• SGPT less than 2 times the upper limit of normal.
• Albumin greater than 75 percent of the lower limit of normal.
• If prior treatment with doxorubicin, the radionuclide or echocardiogram ejection fraction shall be at least 35 percent.
• Performance status 0-2.
• Not in need of current radiation therapy to alleviate local problems.
• No prior exposure to murine antibodies.
• No need for current corticosteroid treatment.